Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA3231
Study Title: A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
CTO #: 104154
NCT Number: NCT06475989
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Thyroid
Study Objectives: To compare progression free survival (PFS) in patients with BRAF V600Em differentiated thyroid cancer who progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.